£8.9M
The financing extension brings Nuclera's total Series C funding to $87m and will advance antibody engineering capabilities.
Nuclera
Nuclera builds desktop bioprinters to accelerate protein expression and research workflows.
£97.3MTotal raised
Nuclera is a biotechnology company based in Cambridge that accelerates protein expression workflows. The firm develops desktop bioprinter technology to streamline protein synthesis for researchers.
Categories
Founders
Michael Chen
CEO
Michael serves as co-founder and chief executive of Nuclera, having previously led the company as chief technology officer. His background includes research roles at the National Institutes of Health and the University of Cambridge.
LinkedInTO
Tobias Ost
Co-founder
Tobias is a co-founder and SVP Product Development at Nuclera. He previously led research and development at Cambridge Epigenetix.
LinkedIn
Gordon McInroy
Gordon is a founder and chief operating officer at Nuclera, having previously held chief technology and chief scientific roles at the company. His background includes research at the University of Cambridge.
LinkedIn
Jiahao Huang
Jiahao co-founded Nuclera, subsequently serving as chief financial officer and board member. He is currently an industry and enterprise fellow at Clare Hall, University of Cambridge.
LinkedInInvestors
- £8.9MGGGK GohFollow-on
- £57.0M
- £31.4M
Funding history
£57.0M
The Series C financing was led by Elevage Medical Technologies with backing from Patient Square Capital and other investors.
£31.4M
The Cambridge biotechnology company has raised £31.4m from investors including M&G and Amadeus Capital Partners to advance its desktop protein printer.